+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Prostate Health Market by Product Type, Indication, End User, Distribution Channel, Technology Type - Global Forecast to 2030- Product Image
Prostate Health Market by Product Type, Indication, End User, Distribution Channel, Technology Type - Global Forecast to 2030- Product Image
Sale

Prostate Health Market by Product Type, Indication, End User, Distribution Channel, Technology Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5639425
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Prostate Health Market grew from USD 57.48 billion in 2024 to USD 63.88 billion in 2025. It is expected to continue growing at a CAGR of 10.84%, reaching USD 106.61 billion by 2030.

Navigating the Evolving Prostate Health Landscape

The growing global burden of prostate conditions demands a fresh lens on therapeutic and diagnostic strategies. Advances in screening protocols, imaging techniques, and personalized treatment modalities have ushered in a new era for prostate health management. Yet, barriers such as limited access to advanced diagnostics, regional regulatory complexities, and evolving patient demographics continue to challenge stakeholders across the value chain.

This summary offers a clear and concise roadmap to navigate these intricacies. It highlights seismic shifts in market dynamics, regulatory headwinds including new United States tariffs, granular segmentation insights, and regional variations that shape investment priorities. With a focus on practical takeaways, this overview equips decision-makers with the knowledge to anticipate emerging trends, optimize resource allocation, and forge collaborations that drive sustainable growth. Through an integrated lens, it sets the foundation for unlocking unprecedented opportunities within the prostate health landscape.

Driving Forces Behind the Proton Health Revolution

Breakthrough technologies and shifting patient expectations are redefining the prostate health ecosystem. High-sensitivity PSA tests now enable earlier detection of malignancies, while advancements in biopsy devices and imaging agents offer unprecedented clarity in lesion characterization. Concurrently, the rise of artificial intelligence in digital pathology and image analysis software is streamlining diagnostic workflows, reducing time to diagnosis, and enhancing accuracy.

On the therapeutic front, the diversification of hormone therapy into androgen receptor antagonists and LHRH agonists, coupled with novel radiopharmaceuticals, is expanding treatment horizons. Personalized medicine initiatives are gaining momentum as biomarker tests such as PCA3 and TMPRSS2-ERG guide targeted interventions. Meanwhile, the convergence of molecular diagnostics with next generation sequencing panels and digital PCR assays is unveiling deeper genomic insights, paving the way for precision care.

These transformative shifts underscore the imperative for stakeholders to embrace innovation across product development, clinical protocols, and reimbursement strategies. As the market recalibrates toward patient-centric solutions, agile partnerships between device manufacturers, diagnostics providers, and pharmaceutical companies will become the cornerstone of competitive advantage.

Navigating the Financial Shockwaves of New Tariff Policies

The introduction of new import tariffs by the United States in 2025 has injected a pronounced ripple effect across the prostate health supply chain. Diagnostic kits sourced from key international suppliers are now subject to higher duties, elevating costs for biopsy devices, imaging agents, and both conventional and high-sensitivity PSA tests. Pharmaceutical stakeholders are also contending with increased expenses for imported chemotherapy agents, hormone therapies, immunotherapies, and radiopharmaceuticals.

These elevated costs are being absorbed through a combination of price adjustments at the end user and strategic realignment of procurement channels. Ambulatory care centers and specialty clinics are seeking alternative sourcing strategies while hospital pharmacies and retail outlets reassess inventory levels. Imaging system vendors are exploring local manufacturing partnerships to mitigate exposure to tariff volatility on computed tomography, magnetic resonance imaging, positron emission tomography, and ultrasound equipment.

Although the immediate impact has been a compression of profit margins for some suppliers, these challenges have spurred a wave of innovation in supply chain resilience. Manufacturers are forging joint ventures, optimizing distribution networks, and investing in regional production hubs. As the tariff landscape continues to evolve, proactive engagement with policy stakeholders and adaptive sourcing models will be critical to sustaining growth and ensuring patient access to advanced prostate health solutions.

Unlocking Growth Through Detailed Market Segmentation

A nuanced understanding of market segments reveals where opportunities and challenges intersect. Within the realm of product type, diagnostic kits span biopsy devices, imaging agents, and PSA tests-with the latter subdivided into conventional and high-sensitivity modalities-while therapeutic options encompass chemotherapy, immunotherapy, radiopharmaceuticals, and hormone therapies that range from androgen receptor antagonists to LHRH agonists. Imaging systems including computed tomography, magnetic resonance imaging, positron emission tomography, and ultrasound (both transabdominal and transrectal) further diversify the landscape.

Examining indications uncovers distinct dynamics for benign prostatic hyperplasia, prostate cancer, and prostatitis. Treatment pathways diverge accordingly, with each condition demanding specialized diagnostic and therapeutic protocols. End users span ambulatory care centers, diagnostic laboratories, hospitals, and specialty clinics, each with unique procurement drivers and clinical workflows. Distribution channels range from direct tenders and hospital pharmacies to online and retail pharmacies, reflecting varied access models and reimbursement frameworks.

Technological advancements in digital pathology, image analysis software, and molecular diagnostics are reshaping market boundaries. Within digital pathology, AI-based analysis and whole slide imaging are accelerating slide review and diagnostic consensus. Molecular diagnostics brings together biomarker tests, next generation sequencing panels, and polymerase chain reaction assays-further refined into digital PCR and real time PCR-to deliver granular genetic insights. Mapping these interrelated segments clarifies the competitive terrain and highlights areas ripe for strategic investment and collaboration.

Regional Variations Shaping Prostate Health Adoption

Regional dynamics exert a powerful influence on the prostate health market’s trajectory. In the Americas, established reimbursement frameworks and advanced clinical infrastructure support rapid adoption of high-sensitivity diagnostics, sophisticated imaging systems, and cutting-edge therapeutics. However, cost containment pressures and payer scrutiny necessitate compelling clinical and economic value propositions.

Across Europe, the Middle East and Africa, regulatory harmonization within the European Union contrasts with disparate access challenges in emerging markets. While Western European nations leverage molecular diagnostics and precision medicine initiatives at scale, pockets of unmet need persist in less developed healthcare systems where access to advanced therapies remains constrained.

In the Asia-Pacific region, rising incidence rates and expanding healthcare budgets are fueling demand for both screening and treatment solutions. Local manufacturing capabilities are growing, and government-led screening programs are accelerating market expansion. Nevertheless, heterogeneous regulatory environments and variable reimbursement policies require calibrated market entry strategies and close partnerships with regional stakeholders.

Competitive Landscape and Collaboration Trends

Leading life science and medical device companies are jockeying to define the next frontier in prostate health. Established players with integrated diagnostic and therapeutic portfolios are leveraging cross-collaborations to deliver end-to-end solutions. Innovative start-ups focused on AI-driven diagnostics and novel biomarker discovery are attracting significant investment as they challenge traditional models.

Partnerships between pharmaceutical giants and specialist diagnostic developers are creating synergistic pathways for companion diagnostics that guide targeted treatments. Equipment manufacturers are embedding advanced software analytics into imaging platforms to differentiate their offerings. Meanwhile, contract research organizations and academic consortia are collaborating on large-scale clinical trials to validate new treatment regimens and emerging imaging agents.

This competitive mosaic underscores the importance of strategic alliances, intellectual property positioning, and clinical evidence development. Companies that can seamlessly combine diagnostic precision with therapeutic efficacy will command a sustainable edge in this dynamic marketplace.

Strategic Imperatives for Market Leadership

Industry leaders must prioritize agility and foresight to capture growing opportunities in prostate health. First, investing in integrated platforms that couple high-sensitivity diagnostics with targeted therapies will enhance clinical utility and differentiate product offerings. Strategic alliances between device manufacturers, molecular diagnostic firms, and pharmaceutical companies can accelerate development timelines and share regulatory burdens.

Second, robust engagement with health authorities and payers is essential to secure favorable reimbursement pathways. Demonstrating real-world clinical and economic value through outcomes research and health economic models will underpin market access strategies. Third, regional adaptability-through localized manufacturing, tailored commercial models, and strategic collaborations-will mitigate geopolitical and tariff-related risks while maximizing local market penetration.

Finally, fostering a culture of innovation through sustained investment in artificial intelligence, next generation sequencing, and radiopharmaceutical research will position companies at the forefront of personalized prostate health solutions. By aligning R&D priorities with evolving patient needs and regulatory trends, organizations can future-proof their portfolios and drive long-term growth.

Methodological Foundation for Insights Credibility

This executive summary is based on a rigorous mixed-methods research design combining primary and secondary data sources. In-depth interviews with oncologists, urologists, pathologists, and health economics experts provided firsthand insights into clinical adoption trends and payer dynamics. Extensive literature reviews of peer-reviewed journals, regulatory filings, and proprietary databases informed our understanding of technological innovations and competitive activity.

Quantitative data were triangulated through analysis of global trade statistics, tariff schedules, and company financial disclosures to assess the impact of 2025 United States import duties. Market segmentation was validated through consultation with industry specialists and cross-referenced against product registries and patent databases. Regional insights were derived from government health ministry reports, reimbursement compendia, and on-the-ground stakeholder interviews across the Americas, Europe, the Middle East, Africa, and Asia-Pacific.

This multi-layered approach ensured a robust, fact-based narrative that accurately reflects current market realities and anticipates emerging trends. The findings presented here have been peer-reviewed by subject matter experts to guarantee methodological integrity and actionable relevance.

Synthesis of Market Dynamics and Opportunity

As prostate health management enters a new phase defined by precision diagnostics and targeted therapies, stakeholders face a complex interplay of technological innovation, regulatory shifts, and economic pressures. The cumulative impact of recent tariff policies underscores the need for resilient supply chains and agile commercial strategies. Simultaneously, advancements in digital pathology, molecular diagnostics, and imaging software are unlocking unprecedented clinical value.

A nuanced understanding of segmentation by product type, indication, end user, distribution channel, and technology platform is indispensable for identifying high-growth niches and crafting differentiated value propositions. Regional heterogeneity in reimbursement, regulatory frameworks, and healthcare infrastructure further accentuates the importance of localized market approaches. Companies that prioritize integrated solutions, strategic collaborations, and proactive payer engagement will be best positioned to lead the market.

This summary provides a concise yet comprehensive snapshot of the prostate health landscape, offering decision-makers the critical insights needed to navigate complexity and seize emerging opportunities.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Diagnostic Kits
      • Biopsy Devices
      • Imaging Agents
      • Psa Tests
        • Conventional
        • High Sensitivity
    • Drugs
      • Chemotherapy
      • Hormone Therapy
        • Androgen Receptor Antagonists
        • Lhrh Agonists
      • Immunotherapy
      • Radiopharmaceuticals
    • Imaging Systems
      • Computed Tomography
      • Magnetic Resonance Imaging
      • Positron Emission Tomography
      • Ultrasound
        • Transabdominal
        • Transrectal
  • Indication
    • Benign Prostatic Hyperplasia
    • Prostate Cancer
    • Prostatitis
  • End User
    • Ambulatory Care Centers
    • Diagnostic Laboratories
    • Hospitals
    • Specialty Clinics
  • Distribution Channel
    • Direct Tender
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Technology Type
    • Digital Pathology
      • Ai Based Analysis
      • Whole Slide Imaging
    • Image Analysis Software
    • Molecular Diagnostics
      • Biomarker Tests
        • Pca3
        • Tmprss2 Erg
      • Next Generation Sequencing Panels
      • Polymerase Chain Reaction Assays
        • Digital Pcr
        • Real Time Pcr
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Astellas Pharma Inc.
  • Pfizer Inc.
  • Johnson & Johnson
  • Bayer AG
  • Novartis AG
  • Ferring International Center S.A.
  • Ipsen S.A.
  • AbbVie Inc.
  • AstraZeneca PLC
  • Merck & Co., Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Prostate Health Market, by Product Type
8.1. Introduction
8.2. Diagnostic Kits
8.2.1. Biopsy Devices
8.2.2. Imaging Agents
8.2.3. Psa Tests
8.2.3.1. Conventional
8.2.3.2. High Sensitivity
8.3. Drugs
8.3.1. Chemotherapy
8.3.2. Hormone Therapy
8.3.2.1. Androgen Receptor Antagonists
8.3.2.2. Lhrh Agonists
8.3.3. Immunotherapy
8.3.4. Radiopharmaceuticals
8.4. Imaging Systems
8.4.1. Computed Tomography
8.4.2. Magnetic Resonance Imaging
8.4.3. Positron Emission Tomography
8.4.4. Ultrasound
8.4.4.1. Transabdominal
8.4.4.2. Transrectal
9. Prostate Health Market, by Indication
9.1. Introduction
9.2. Benign Prostatic Hyperplasia
9.3. Prostate Cancer
9.4. Prostatitis
10. Prostate Health Market, by End User
10.1. Introduction
10.2. Ambulatory Care Centers
10.3. Diagnostic Laboratories
10.4. Hospitals
10.5. Specialty Clinics
11. Prostate Health Market, by Distribution Channel
11.1. Introduction
11.2. Direct Tender
11.3. Hospital Pharmacies
11.4. Online Pharmacies
11.5. Retail Pharmacies
12. Prostate Health Market, by Technology Type
12.1. Introduction
12.2. Digital Pathology
12.2.1. Ai Based Analysis
12.2.2. Whole Slide Imaging
12.3. Image Analysis Software
12.4. Molecular Diagnostics
12.4.1. Biomarker Tests
12.4.1.1. Pca3
12.4.1.2. Tmprss2 Erg
12.4.2. Next Generation Sequencing Panels
12.4.3. Polymerase Chain Reaction Assays
12.4.3.1. Digital Pcr
12.4.3.2. Real Time Pcr
13. Americas Prostate Health Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Prostate Health Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Prostate Health Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Astellas Pharma Inc.
16.3.2. Pfizer Inc.
16.3.3. Johnson & Johnson
16.3.4. Bayer AG
16.3.5. Novartis AG
16.3.6. Ferring International Center S.A.
16.3.7. Ipsen S.A.
16.3.8. AbbVie Inc.
16.3.9. AstraZeneca PLC
16.3.10. Merck & Co., Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. PROSTATE HEALTH MARKET MULTI-CURRENCY
FIGURE 2. PROSTATE HEALTH MARKET MULTI-LANGUAGE
FIGURE 3. PROSTATE HEALTH MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PROSTATE HEALTH MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PROSTATE HEALTH MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PROSTATE HEALTH MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. PROSTATE HEALTH MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. PROSTATE HEALTH MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PROSTATE HEALTH MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PROSTATE HEALTH MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BIOPSY DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PROSTATE HEALTH MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HIGH SENSITIVITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PROSTATE HEALTH MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ANDROGEN RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PROSTATE HEALTH MARKET SIZE, BY LHRH AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PROSTATE HEALTH MARKET SIZE, BY RADIOPHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PROSTATE HEALTH MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PROSTATE HEALTH MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PROSTATE HEALTH MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TRANSABDOMINAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TRANSRECTAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PROSTATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PROSTATE HEALTH MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL PROSTATE HEALTH MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL PROSTATE HEALTH MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL PROSTATE HEALTH MARKET SIZE, BY AI BASED ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL PROSTATE HEALTH MARKET SIZE, BY WHOLE SLIDE IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL PROSTATE HEALTH MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PCA3, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TMPRSS2 ERG, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL PROSTATE HEALTH MARKET SIZE, BY NEXT GENERATION SEQUENCING PANELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 96. CANADA PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 97. CANADA PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2030 (USD MILLION)
TABLE 98. CANADA PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2018-2030 (USD MILLION)
TABLE 99. CANADA PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 100. CANADA PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 101. CANADA PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 102. CANADA PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 103. CANADA PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. CANADA PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. CANADA PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. CANADA PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 107. CANADA PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 108. CANADA PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 109. CANADA PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2018-2030 (USD MILLION)
TABLE 110. CANADA PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2018-2030 (USD MILLION)
TABLE 111. MEXICO PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 112. MEXICO PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2030 (USD MILLION)
TABLE 113. MEXICO PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2018-2030 (USD MILLION)
TABLE 114. MEXICO PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 115. MEXICO PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 116. MEXICO PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 117. MEXICO PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 118. MEXICO PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. MEXICO PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. MEXICO PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. MEXICO PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 122. MEXICO PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 123. MEXICO PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 124. MEXICO PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2018-2030 (USD MILLION)
TABLE 125. MEXICO PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 172. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2030 (USD MILLION)
TABLE 174. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2018-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 176. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 178. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 180. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2018-2030 (USD MILLION)
TABLE 187. GERMANY PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 188. GERMANY PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2030 (USD MILLION)
TABLE 189. GERMANY PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2018-2030 (USD MILLION)
TABLE 190. GERMANY PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 191. GERMANY PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 192. GERMANY PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 193. GERMANY PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 194. GERMANY PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 195. GERMANY PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. GERMANY PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. GERMANY PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 198. GERMANY PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 199. GERMANY PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 200. GERMANY PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2018-2030 (USD MILLION)
TABLE 201. GERMANY PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2018-2030 (USD MILLION)
TABLE 202. FRANCE PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 203. FRANCE PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2030 (USD MILLION)
TABLE 204. FRANCE PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2018-2030 (USD MILLION)
TABLE 205. FRANCE PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 206. FRANCE PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 207. FRANCE PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 208. FRANCE PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 209. FRANCE PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 210. FRANCE PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. FRANCE PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. FRANCE PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 213. FRANCE PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 214. FRANCE PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 215. FRANCE PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2018-2030 (USD MILLION)
TABLE 216. FRANCE PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2018-2030 (USD MILLION)
TABLE 217. RUSSIA PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 218. RUSSIA PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2030 (USD MILLION)
TABLE 219. RUSSIA PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2018-2030 (USD MILLION)
TABLE 220. RUSSIA PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 221. RUSSIA PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 222. RUSSIA PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 223. RUSSIA PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 224. RUSSIA PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 225. RUSSIA PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. RUSSIA PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. RUSSIA PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2018-2030 (USD MILLION)
TABLE 232. ITALY PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 233. ITALY PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2030 (USD MILLION)
TABLE 234. ITALY PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2018-2030 (USD MILLION)
TABLE 235. ITALY PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 236. ITALY PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 237. ITALY PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 238. ITALY PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 239. ITALY PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 240. ITALY PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. ITALY PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. ITALY PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 243. ITALY PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 244. ITALY PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 245. ITALY PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2018-2030 (USD MILLION)
TABLE 246. ITALY PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2018-2030 (USD MILLION)
TABLE 247. SPAIN PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 248. SPAIN PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2030 (USD MILLION)
TABLE 249. SPAIN PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2018-2030 (USD MILLION)
TABLE 250. SPAIN PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 251. SPAIN PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 252. SPAIN PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 253. SPAIN PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 254. SPAIN PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 255. SPAIN PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. SPAIN PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. SPAIN PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 258. SPAIN PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 259. SPAIN PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 260. SPAIN PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2018-2030 (USD MILLION)
TABLE 261. SPAIN PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2018-2030 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2030 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2018-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2018-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 278. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2018-2030 (USD MILLION)
TABLE 280. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 281. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 282. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 283. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 284. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 285. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 288. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 289. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 290. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2018-2030 (USD MILLION)
TABLE 291. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2018-2030 (USD MILLION)
TABLE 292. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 293. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2030 (USD MILLION)
TABLE 294. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2018-2030 (USD MILLION)
TABLE 295. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 296. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 297. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 298. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 299. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 300. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 303. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 304. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 305. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2018-2030 (USD MILLION)
TABLE 306. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2018-2030 (USD MILLION)
TABLE 307. DENMARK PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 308. DENMARK PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2030 (USD MILLION)
TABLE 309. DENMARK PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2018-2030 (USD MILLION)
TABLE 310. DENMARK PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 311. DENMARK PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 312. DENMARK PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 313. DENMARK PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 314. DENMARK PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 315. DENMARK PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. DENMARK PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 317. DENMARK PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 318. DENMARK PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 319. DENMARK PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 320. DENMARK PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2018-2030 (USD MILLION)
TABLE 321. DENMARK PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2018-2030 (USD MILLION)
TABLE 322. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 323. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2030 (USD MILLION)
TABLE 324. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2018-2030 (USD MILLION)
TABLE 325. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 326. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 327. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 328. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 329. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 330. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 331. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 332. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 333. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 334. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 335. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY BIOMARKER TESTS, 2018-2030 (USD MILLION)
TABLE 336. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY POLYMERASE CHAIN REACTION ASSAYS, 2018-2030 (USD MILLION)
TABLE 337. QATAR PROSTATE HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 338. QATAR PROSTATE HEALTH MARKET SIZE, BY DIAGNOSTIC KITS, 2018-2030 (USD MILLION)
TABLE 339. QATAR PROSTATE HEALTH MARKET SIZE, BY PSA TESTS, 2018-2030 (USD MILLION)
TABLE 340. QATAR PROSTATE HEALTH MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 341. QATAR PROSTATE HEALTH MARKET SIZE, BY HORMONE THERAPY, 2018-2030 (USD MILLION)
TABLE 342. QATAR PROSTATE HEALTH MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 343. QATAR PROSTATE HEALTH MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 344. QATAR PROSTATE HEALTH MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 345. QATAR PROSTATE HEALTH MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 346. QATAR PROSTATE HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Prostate Health market report include:
  • Astellas Pharma Inc.
  • Pfizer Inc.
  • Johnson & Johnson
  • Bayer AG
  • Novartis AG
  • Ferring International Center S.A.
  • Ipsen S.A.
  • AbbVie Inc.
  • AstraZeneca PLC
  • Merck & Co., Inc.

Table Information

Report AttributeDetails
No. of Pages186
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 63.88 Billion
Forecasted Market Value ( USD ) by 2030 $ 106.61 Billion
Compound Annual Growth Rate10.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Prostate Cancer Diagnostics Market by Product Type, Test Type, End User, Technology, Application - Global Forecast to 2030 - Product Image

Prostate Cancer Diagnostics Market by Product Type, Test Type, End User, Technology, Application - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global
From
Prostate Cancer Biomarkers Market Size, Share & Trends Analysis Report by Type (Genetic Biomarkers, Cell-based Biomarkers, Metabolomic Biomarkers), Application, End-use, Region, with Growth Forecasts, 2025-2030 - Product Image

Prostate Cancer Biomarkers Market Size, Share & Trends Analysis Report by Type (Genetic Biomarkers, Cell-based Biomarkers, Metabolomic Biomarkers), Application, End-use, Region, with Growth Forecasts, 2025-2030

  • Report
  • 120 Pages
  • Global
From
Total Prostate Specific Antigen Assay Kit Market by Technology, End Use, Application, Sample Type, Sales Channel - Global Forecast to 2030 - Product Image

Total Prostate Specific Antigen Assay Kit Market by Technology, End Use, Application, Sample Type, Sales Channel - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global
From
Prostate Cancer - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Prostate Cancer - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Prostate Cancer Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Prostate Cancer Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From

About the Prostate Health Market

The Prostate Health market is a subset of the pharmaceutical industry focused on the development and sale of drugs to treat prostate cancer. Prostate cancer is the most common cancer in men, and the drugs used to treat it are typically hormone therapy, chemotherapy, and radiation therapy. These drugs are used to reduce the size of the tumor, slow its growth, and reduce the risk of metastasis. In addition, some drugs are used to reduce the side effects of prostate cancer treatments, such as fatigue, nausea, and sexual dysfunction. The Prostate Health market is highly competitive, with many companies offering a variety of drugs to treat prostate cancer. Some of the major players in the market include AstraZeneca, Pfizer, Merck, and Johnson & Johnson. Other companies in the market include AbbVie, Bristol-Myers Squibb, and Sanofi. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.